Application of mutagen sensitivity assay in a glioma case-control study.

Published online

Journal Article

Few risk factors for glioma have been identified other than ionizing radiation. The alkylating agent acrylamide is a compound found in both occupational and the general environment and identified as one of the forty known or suspected neurocarcinogens in animal models. The mutagen sensitivity assay (MSA) has been used to indirectly show reduced DNA repair capacity upon exposure to ionizing radiation in those with glioma compared to controls. In this study, MSA was used to assess its applicability to a glioma case-control study and to test the hypothesis that subjects with glioma may have lower DNA repair capacity after exposure to selected potential human neurocarcinogens (i.e. acrylamide), compared to controls. Approximately 50 case and 50 control subjects were identified from a clinic-based study that investigated environmental risk factors for glioma, who completed an exposure survey, and had frozen immortalized lymphocytes available. A total of 50 metaphase spreads were read and reported for each participant. The association of case-control status with MSA for acrylamide, i.e. breaks per spread, was examined by multivariable logistic regression models. The mean number of breaks per slide was similar between hospital-based controls and cases. In addition, case-control status or exposure categories were not associated with the number of breaks per spread. Although the MSA has been shown as a useful molecular epidemiology tool for identifying individuals at higher risk for cancer, our data do not support the hypothesis that glioma patients have reduced DNA repair capacity in response to exposure to acrylamide. Further research is needed before the MSA is utilized in large-scale epidemiological investigations of alkylating agents.

Full Text

Duke Authors

Cited Authors

  • Erdal, S; McCarthy, BJ; Gurule, N; Berwick, M; Gonzales, E; Byrd, J; Flores, K; Shimek, J; Il'yasova, D; Ali-Osman, F; Bigner, DD; Davis, FG; Leyba, AN; White, KAM

Published Date

  • 2018

Published In

Volume / Issue

  • 5 /

Start / End Page

  • 183 - 188

PubMed ID

  • 29854587

Pubmed Central ID

  • 29854587

Electronic International Standard Serial Number (EISSN)

  • 2214-7500

Digital Object Identifier (DOI)

  • 10.1016/j.toxrep.2017.12.010


  • eng

Conference Location

  • Ireland